Navigation Links
Shire plc : Second Quarter 2011 Results Date Notification - July 28, 2011
Date:7/15/2011

DUBLIN, July 15, 2011 /PRNewswire/ --


 

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2011 earnings on Thursday July 28, 2011.

Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 BST/9:00 EDT.

The details of the conference call are as follows:

UK dial in: 0800-077-8492 or 0844-335-0351 US dial in: +1-866-8048688 or +1-718-3541175 International dial in: +44-208-974-7900

Global Access Numbers:    http://www.btconferencing.com/globalaccess/?bid=54_attended

Password/Conf ID:    818 608

Live Webcast:    http://www.shire.com/shireplc/en/investors

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year.  Details can be found on our Investor Relations website http://www.shire.com/shireplc/en/investors.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

Investor Relations Souheil Salah (ssalah@shire.com) +44-1256-894-160 Erin Kelly (erikelly@shire.com) +1-781-482-9541


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents
2. United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk
3. Shire Completes Acquisition of Advanced BioHealing, Inc.
4. European Authorities Approve New Manufacturing Facility for Shires REPLAGAL® (agalsidase alfa)
5. Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
6. Shire Recognized by ISPE Facility of the Year Awards Program
7. Reportlinker Adds Shire plc: PharmaVitae Profile
8. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
9. Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
10. Atrium Recognized by New Hampshire Bio/Medical Council
11. Shire Update on ProAmatine(R) (midodrine HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017  Eli Lilly and Company (NYSE: ... invest $850 million in its U.S. operations in ... U.S. enterprise, including research laboratories, manufacturing sites, and ... driven by demand for Lilly products, as well ... development targeting cancer, pain, diabetes and other unmet ...
(Date:3/24/2017)... YORK and GENEVA , ... announced on World Tuberculosis Day revitalizes efforts to develop ... On World Tuberculosis Day, TB Alliance and ... for the clinical development of sutezolid, an antibiotic drug ... sublicense pertains to the development of sutezolid in combination ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 ... are growing ageing population, increasing diabetic population, accelerating economic growth ... developments of this industry are higher life expectancy of ESRD ... potential in emerging markets. However, the expansion of the market ... ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the opening ... is the group’s 7th location in San Antonio and 23rd in Texas. Dr. ... from the clinic, which opened March 22, 2017. , The team of ...
(Date:3/24/2017)... Pittsburgh, PA (PRWEB) , ... March 24, 2017 ... ... the Oncology Nursing Society (ONS) wanted to create a communications platform that positions ... realize this goal, Elliance and ONS reinvented their online publication as an always-on, ...
(Date:3/24/2017)... ... 24, 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ... for colonoscopy at the HyGIeaCare® Center that is to be located adjacent to ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), ...
(Date:3/24/2017)... ... 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian Love” is ... residing in North Carolina with his wife, Anna Marie. He and his wife are ... David is also the author of “Shadow and Substance.” , “Love, the agape kind, ...
Breaking Medicine News(10 mins):